Lilly Launches Foundayo™: New Oral GLP-1 Weight Loss Pill Hits U.S. Market
Eli Lilly’s new oral medication, Foundayo (orforglipron), is now available to U.S. adults with obesity. The drug received FDA approval on April 1, 2026. Distribution expanded through LillyDirect, telehealth providers, and retail pharmacies beginning April 9, 2026.
Lilly launches Foundayo as a once-daily, non-peptide GLP-1 receptor agonist. The pill can be taken any time without food or water restrictions. It is intended alongside a reduced-calorie diet and increased physical activity.
Availability and cost
Foundayo ships via LillyDirect with free home delivery for qualifying patients. Telehealth providers can prescribe the medicine. Retail pharmacies nationwide began receiving shipments on April 9, 2026.
Self-pay patients can access the lowest dose starting at $149 per month. Commercially insured patients with coverage may pay as little as $25 per month using a savings card. Medicare Part D beneficiaries may be eligible for a $50 monthly copay beginning July 1, 2026.
Clinical evidence
The ATTAIN Phase 3 program enrolled more than 4,500 adults globally. Two registration trials, ATTAIN-1 and ATTAIN-2, each ran 72 weeks.
In ATTAIN-1, participants on the highest dose who remained on treatment lost an average 27.3 pounds. That represented a 12.4% reduction from baseline versus 2.2 pounds (0.9%) with placebo. Across participants regardless of completion, Foundayo produced an average 25-pound loss (11.1%) versus 5.3 pounds (2.1%) with placebo.
The program also recorded reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across doses. ATTAIN-1 enrolled 3,127 people without diabetes across multiple countries. ATTAIN-2 enrolled over 1,600 adults with obesity or overweight and type 2 diabetes.
Safety and prescribing guidance
Foundayo is not recommended with other GLP-1 receptor agonists. Safety in children has not been established. The drug may cause thyroid tumors, including thyroid cancer.
- Watch for neck lumps, hoarseness, trouble swallowing or shortness of breath.
- Do not use if you or a family member had medullary thyroid carcinoma or MEN 2.
- Serious risks include pancreatitis, severe stomach problems, dehydration-related kidney injury, and low blood sugar if combined with insulin or sulfonylureas.
Common side effects include nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain. Other reported effects are headache, bloating, fatigue, belching, heartburn, gas and hair loss.
Use during pregnancy and contraception
Foundayo may harm an unborn baby. A pregnancy exposure registry will collect data on women exposed during pregnancy. Oral contraceptives may be less effective. Alternative contraception is recommended for 30 days after starting Foundayo and after dose increases.
Administration and formulation
Take Foundayo orally once each day. It may be taken with or without food. Swallow the tablet whole and do not take more than one tablet per day.
Available tablet strengths include 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg. If you miss seven or more consecutive days, contact your healthcare provider about restarting treatment.
Development and pipeline
Orforglipron was discovered by Chugai Pharmaceutical and licensed to Lilly in 2018. Lilly is studying the molecule for other conditions. These include type 2 diabetes, obstructive sleep apnea, knee osteoarthritis pain, hypertension, peripheral artery disease and stress urinary incontinence.
Healthcare professionals and patients seeking more information can contact Lilly directly or visit the official Foundayo site. Filmogaz.com provided reporting on the launch and availability.
